News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kamada Ltd. (KMDA.TA) Completes Enrollment In U.S. Pivotal Clinical Trial With Kamrab As A Post-Exposure Treatment For Rabies


3/4/2014 10:06:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (Nasdaq:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, focused on orphan indications, announces that it has completed enrollment in its U.S. Phase 2/3 clinical trial of KamRAB® as a post-exposure prophylaxis (PEP) for rabies.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES